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Abstract
Introduction: B7-H1 (PD-L1, CD274) is a T cell inhibitory molecule expressed in many types of cancer, leading to 
immune escape of tumor cells. Indeed, in previous reports we have shown an association of B7-H1 expression with 
high-risk breast cancer patients.
Methods: In the current study, we used immunohistochemistry, immunofluorescence and Western blot techniques to 
investigate the effect of neoadjuvant chemotherapy on the expression of B7-H1 in breast cancer cells.
Results: Among tested chemotherapeutic agents, doxorubicin was the most effective in downregulating cell surface 
expression of B7-H1 in vitro. These results were validated in vivo in a xenograft mouse model, as well as in murine heart 
tissue known to constitutively express B7-H1. The doxorubicin-dependent cell surface downregulation of B7-H1 was 
accompanied by an upregulation of B7-H1 in the nucleus. This re-distribution of B7-H1 was concurrent with a similar 
translocation of phosphorylated AKT to the nucleus. Inhibition of the PI3K/AKT pathway abrogated the doxorubicin-
mediated nuclear up-regulation of B7-H1, suggesting an involvement of PI3K/AKT pathway in the nuclear up-
regulation of B7-H1. Interestingly, siRNA knock down of B7-H1 lead to an increase in spontaneous apoptosis, as well as 
doxorubicin-induced apoptosis, which indicates an anti-apoptotic role for B7-H1 in breast cancer cells. The novel 
discovery of B7-H1 expression in the nuclei of breast cancer cells suggests that B7-H1 has functions other than 
inhibition of T cells.
Conclusions: Our findings explain the previously reported immunomodulatory effect of anthracyclines on cancer 
cells, and provide a link between immunoresistance and chemoresistance. Finally these results suggest the use of dual 
combinatorial agents to inhibit B7-H1 beside chemotherapy, in breast cancer patients.
Introduction
Anthracyclines rank amongst the most effective anti can-
cer drugs ever developed [1]. Whereas doxorubicin is an
essential component of treatment for breast cancer [2],
childhood solid tumors, soft tissue sarcomas and aggres-
sive lymphomas [3,4], daunorubicin shows activity in
acute lymphoblastic or myeloblastic leukemias [5]. Like
many chemotherapeutic drugs, anthracyclines kill cancer
cells by direct cytotoxicity. Nevertheless, there is accu-
mulating evidence that these agents also have immuno-
augmenting effects, through both the innate as well as the
adaptive immune system, that might help in the therapy
of cancer [6]. Doxorubicin stimulates cytokines produc-
tion, augments natural killer (NK) cells activity [7], stimu-
lates cytotoxic T-lymphocyte (CTL) responses [8] and
augments differentiation of macrophages [9], all of which
are important components of an effective immune
response. Recently, the unique ability of doxorubicin,
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daunorubicin and mitoxantrone to make cancer cells
immunogenic was shown to be through calreticulin re-
localization to the cell surface [10] and the selective
induction and release of High-mobility group box 1
(HMGB1) protein from dying cancer cells [11].
The mainstay of the adaptive immune system is the
antigen presentation of processed peptides by antigen
presenting cells (APC) [12,13]. Recognition of a T cell
receptor of a peptide presented on MHC molecules of an
APC provides the first signal. However, the optimal acti-
vation of a T lymphocyte requires a second signal pro-
vided by co-stimulatory molecules, which are normally
balanced with inhibitory molecules [14]. The balance of
positive and negative signals is of central importance in
maximizing the ability of the adaptive immune response
to defend the host, while maintaining tolerance and pre-
venting autoimmunity [15]. One of the recently identified
novel T lymphocyte inhibitory molecules is the cell sur-
face glycoprotein called B7-H1 (also called PD-L1 and
CD274). B7-H1 is expressed on APCs and binds to its
ligand on T lymphocytes leading to both inhibition and
induction of apoptosis in effector T lymphocytes [15], or
induction of anergy in naïve T lymphocytes [16-18].
The aberrant expression of B7-H1 in tumor tissues has
been reported in various cancers [19]. Our group has
recently reported on the aberrant B7-H1 expression in
breast cancer tissues and its association with high-risk
prognostic factors [20]. In the current study we examine
the effect of chemotherapeutic agents, commonly used
for treatment of breast cancer, on the expression level of
B7-H1 in breast cancer cells. We have shown doxorubi-
cin-dependent downregulation of cell surface B7-H1 and
its translocation to the nucleus concomitant with the
translocation of the phospho-AKT. Finally, we provide
evidence that B7-H1 has an anti-apoptotic role in doxo-
rubicin-treated breast cancer cells.
Materials and methods
Drug treatment of cultured cell lines and AKT 
phosphorylation inhibition
MDA-MB-231, SKBR-3 and T47 D cells (ATCC) were
cultured in Dulbecco's Modified Eagle's Medium
( DM EM)  wit h 10% FCS.  C e l ls  we r e  seeded a t  2 ×  10 4
cells/cm2. Doxorubicin, Daunorubicin, Mitoxantrone,
Cisplatin (Sigma, St. Louis, MO, USA) and Docetaxel
(Aventis Pharma, Bridgewater, NJ, USA) were added to
the cells at 60 to 80% confluence. Cells were incubated
with the drug for 24 to 72 hours. AKT phosphorylation
was inhibited using LY294002 (calbiochem) at 20 μM.
Measurement of B7-H1 expression and apoptosis
B7-H1 expression was assessed by FACS analysis of allo-
phycocyanin-labeled anti-B7-H1 (eBioscience, San Diego,
CA, USA) or Phycoerythrin -labeled B7-H1 (eBioscience)
to eliminate the interference of the natural fluorescence
of the drug [21,22]. Cells were incubated with anti-B7-H1
for 45 minutes before FACS analysis. Cell-viability was
measured using 1.5 μg/mL propidium iodide. For the
apoptosis assay, cells were doublestained with anti-B7-H1
antibody and Annexin V (Apoptosis Assay Kit system,
Molecular Probe, Eugene, OR, USA). luorescence was
measured using LSR I FACS system (BD Biosciences, San
Jose, CA, USA) and analyzed using Cell Quest Pro analy-
sis software (BD Biosciences).
Measurement of cell proliferation
MDA-MB-231 cells were cultured in a 96-well plate
(10,000 cells/well) for 24 hours followed by the addition
of  3H-thymidine (Amersham, Chiltern Hills, London,
UK) at 1 μCi/well for 18 hours before harvesting. 3H-thy-
midine uptake was measured using a 1450 Micro Beta
PLUS liquid scintillation counter (Wallac, Waltham, Mas-
sachusetts, USA).
Western blot analysis
Cells were lysed and cell membrane proteins were sepa-
rated using a membrane protein extraction kit (Biovision,
Mountain View, California, USA). Cytoplasmic and
nuclear protein extracts were prepared as previously pub-
lished [23]. Immunoblotting was performed as described
previously [24]. Anti-B7-H1 (MIH1 clone, eBioscience)
was used at 1:500 dilutions and Anti-GAPDH (FL-335
clone, Santa Cruz, Santa Cruz, CA, USA) was used at
1:4000 dilution.
Immunofluorescence
MDA-MB-231 cells cultured on collagen type I (BD Bio-
sciences) coated slides were treated with doxorubicin for
72 hours. The slides were washed, dried and fixed in ace-
tone. Cells were stained overnight with anti-B7-H1 at
1:50. Cells were washed and stained with biotinylated
polyclonal antibody (Ultratech, San Jose, CA, USA) for 30
minutes. After washing, streptavidin- fluorescein isothio-
cyanate (FITC) (BD Biosciences) was added at 1:100 for
30 minutes. Phosphorylated AKT (phospho-AKT) stain-
ing was carried out by fixing cells in 1% paraformalde-
hyde, washing in permeabilization buffer (eBioscience)
and one-hour incubation with rabbit anti-phospho-AKT
(Ser473 site, Cell Signaling, Danvers, MA, USA). After
washing, cells were incubated with FITC-goat-anti rabbit-
antibody (Serotec, Raleigh, NC, USA) at 1:10 for 30 min-
utes. 300 nM DAPI (Invitrogen, Carlsbad, CA, USA) was
added for 10 minutes to counterstain the nuclei. Slides
were mounted and immunofluorescence was visualized
using confocal microscope (Perkin Elmer Ultraview, Cov-
ina, CA, USA). Cytoplasmic and nuclear AKT were quan-
tified with manual counting from printed images.Ghebeh et al. Breast Cancer Research 2010, 12:R48
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Mice xenotransplantation and drug treatment
Nude mice (Jackson Laboratories, Bar Harbor, Maine,
USA) were injected with 106 cells of MDA-MB-231 in the
mammary pad and tumor size was measured weekly
using a caliper. When the tumor reached approximately 7
mm diameter (four to five weeks), mice were treated with
doxorubicin (10 mg/Kg) via tail vein injection. After three
or five days, the mice were sacrificed and tumor and heart
tissues were excised, embedded in OCT, snap frozen in
liquid nitrogen and stored at -80°C before use. The breed-
ing, care and sacrifice of the animals were in accordance
with the protocols approved by the Animal Care and Use
Committee of the King Faisal Specialist Hospital and
Research Centre.
Immunohistochemistry
Mouse tumor and heart tissues were stained using rabbit
anti-B7-H1 (LifeSpan BioSciences, Seattle, WA, USA) at
1:2000 followed by HRP-Envision anti-rabbit-polymer
(Dako, Carpinteria, CA, USA) as previously described
[25]. Color was visualized with DAB (Ultratech) and
nuclei were counterstained with instant hematoxylin
(Shandon, Bohemia, NY, USA).
B7-H1 siRNA treatment of cells
B7-H1 expression was inhibited in MDA-MB-231 cells
using a specific siRNA (CD274 siRNA ID = s26547 and
siRNA ID = s26548, Ambion, Austin, TX, USA). During
siRNA transfection, cells were inoculated at a density of
20 × 103  cells/cm2  in OPTI-MEM medium (GIBCO,
Grand Island, NY, USA). Cells were allowed to grow for
two days before drug treatments.
Statistical analysis
Significance for B7-H1 expression in Neoadjuvant treated
and non-treated patients were calculated using unpaired
T-test using GraphPadPrism4 software, GraphPad Soft-
ware, Inc., La Jolla, CA, USA). P < 0.05 cut-off was used
to indicate significance.
Results
Doxorubicin down-regulates cell surface expression of B7-
H1 in vitro
Currently, our standard neoadjuvant chemotherapy for
locally advanced breast cancer patients involves doxoru-
bicin, docetaxel and cyclophosphamide with some of the
clinical trial enrolled patients receiving a combination of
doxorubicin and cisplatin [26]. Cyclophosphamide being
a prodrug, that is, an inactive compound that becomes
activated only in vivo, we only tested the other three
drugs on the expression of B7-H1. We used the two
breast cancer cell lines (MDA-MB-231 and SKBr3)
known to constitutively express B7-H1. Figure 1A, B
shows a dose-dependent effect of these drugs on the cell
surface expression of B7-H1. Doxorubicin treatment sig-
nificantly down regulates B7-H1 expression, by approxi-
mately 80% at 0.4 ug/ml (Figure 1A). On the other hand
docetaxel and cisplatin had no effect on the B7-H1 cell
surface expression (see Figure 1A). The effect of doxoru-
bicin on B7-H1 downregulation was time dependent
reaching a 90% inhibition after 72 hours incubation (Fig-
ure 1C). In order to determine if the effect of Doxorubicin
is shared by other members of the anthracycline family
we tested the effect of daunorubicin, another member of
the anthracyclines family which was found to have a
strong downregulatory effect on the cell surface expres-
sion of B7-H1. Mitoxantrone, an immunomodulatory
drug, had no significant effect on B7-H1 expression (Fig-
ure 1D).
Doxorubicin-dependent cell surface downregulation of B7-
H1 expression is not due to apoptosis or cell proliferation
One of the known mechanisms of chemotherapeutic
agents is to arrest the cell cycle thus stopping the prolifer-
ation of cells. Previously, we showed an association
between B7-H1 expression and cell proliferation [27].
Therefore, we investigated whether the effect of doxoru-
bicin on decreasing the B7-H1 was due to its effect on the
proliferation by comparing the effect of docetaxel and
doxorubicin on cell proliferation. Figure 2A shows that
both drugs stopped MDA-MB-231 cell proliferation at
the lowest tested concentration (0.05 ug/mL). However,
B7-H1 expression is hardly effected at this concentration
as shown in Figure 1A.
It is commonly known that apoptosis induces several
changes in the cell membrane leading to redistribution of
phosphatidylserine to the extra-cellular surface [28] and
probably also other surface molecules. To test whether
such a decrease in the cell surface expression of B7-H1 is
due to apoptotic cell membrane redistribution of mem-
brane molecules, we double-stained for B7-H1 and
annexin V, a molecule that binds to negatively charged
phosphatidylserine and thus labels apoptotic cells. Figure
2B shows MDA-MB-231 cells treated with doxorubicin or
docetaxel for 72 hours and double-labeled with B7-H1
and Annexin V. Doxorubicin downregulated B7-H1 in
both apoptotic and non-apoptotic cells. Interestingly,
doxorubicin treatment resulted in a significant increase
in apoptosis, mainly in the B7-H1 negative population.
Furthermore, while both drugs induce apoptosis in a dose
dependent manner, only doxorubicin downregulated B7-
H1 expression, indicating that B7-H1 cell surface down-
regulation is independent of membrane redistribution of
phospholipids. Altogether these results suggest that the
downregulatory effect of doxorubicin on the surface
expression of B7-H1 is specific and not due to apoptosis
mediated membrane re-distribution of phospholipids or
blockage of cell proliferation.Ghebeh et al. Breast Cancer Research 2010, 12:R48
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Downregulation of cell surface expression of B7-H1 after 
doxorubicin treatment is due to cellular redistribution
The above data demonstrated a downregulation of cell
surface expression of B7-H1 in breast cancer cells after
treatment with doxorubicin as assessed by flow cytome-
try. To investigate the mechanism of this downregulation,
we measured the B7-H1 mRNA using RT-PCR of the
total RNA collected from cells treated with two doses of
doxorubicin (0.4 and 0.8 μg/mL). There was no signifi-
cant change in the level of the B7-H1 mRNA (data not
shown). We further studied the redistribution of the B7-
H1 protein into the cells by staining a monolayer of
MDA-MB-231 cells with immunofluorescence labeled
B7-H1 and examining the cells under confocal micro-
scope. Untreated cells had membranous/cytoplasmic
expression of B7-H1 with predominant staining in the
cytoplasm close to the nuclear membrane, possibly the
endoplasmic reticulum. In the nucleus, a very low expres-
sion of B7-H1 could be seen in the small field image (Fig-
ure 3A). However, after treatment with 0.4 μg/mL
doxorubicin, the expression of B7-H1 was more localized
to the nuclei (in more > 95% of the cells) with some
expression in the cytoplasm. At 1.6 μg/mL of doxorubicin
there was a predominant expression of B7-H1 in the cell
nuclei. Consistent with the flow cytometry data, doc-
etaxel did not decrease the cell surface expression of B7-
H1 (Figure 3A). To further confirm B7-H1 redistribution
after treatment we extracted proteins from the mem-
brane, cytoplasm and the nucleus of the cells and mea-
sured B7-H1 expression in these fractions using western
blot before and after treatment. Figure 3B shows a three-
fold decrease in the level of B7-H1 in the membrane and a
five-fold decrease in the level of B7-H1 in the cytoplasmic
fractions However there was a two-fold increase in the
level of B7-H1 in the nuclear fraction after doxorubicin
treatment. These results were also seen with other cell
lines that express very low levels of B7-H1 on the cell sur-
face like T47 D (Figure 3C). Altogether the confocal
microscopy and the Western blot data clearly demon-
Figure 1 The effect of chemotherapy on B7-H1 expression in breast cancer cell lines. A) Dose dependent effect of chemotherapy in MDA-MB-
231 and SKBr3 cells treated for 72 hours (n = 3). B) Representative FACS histograms for the effect of doxorubicin on MDA-MB-231 cells. C) Time de-
pendent effect of doxorubicin (0.8 μg/mL) on MDA-MB-231 cells (n = 3). D) The Effect of different drugs on B7-H1 expression in MDA-MB-231 cells 
treated for 72 hours (n = 2). Doxo, doxorubicin; DAUN, daunorubicin; and MITO, mitoxantrone.
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Figure 2 The effect of chemotherapy on the survival and proliferation of cells. A) The Effect of doxorubicin and docetaxel on the proliferation 
of MDA-MB-231 after 72 hours culture using 3H-thymidine uptakes. Counts (cpm) were normalized to untreated control and expressed as percentage 
of control. B) B7-H1 expression after doxorubicin treatment in apoptotic and non-apoptotic cells. Cells were treated with doxorubicin or docetaxel for 
72 hours, doublestained with annexin V and B7-H1 and analyzed by FACs.
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strated a doxorubicin-dependent re-distribution of B7-
H1 from the membrane to nucleus.
Re-distribution of B7-H1 from the membrane to the 
nucleus is associated with translocation of p-AKT to the 
nucleus
Several reports have previously shown a direct relation-
ship between the AKT activation pathway and B7-H1
expression, and these studies demonstrated that B7-H1 is
a downstream target of AKT in glioma and breast cancer
cells [29,30]. In the present study, we measured phospho-
AKT and total AKT after doxorubicin treatment of
MDA-MB-231 cells using Western blot analysis. There
was no change in phospho-AKT levels in the membrane
and cytoplasm fractions; however, there was an increase
in total AKT in these fractions resulting in a decrease of
phospho-AKT over total AKT (Figure 3D). In contrast,
there was an increase in both nuclear phospho-AKT and
total AKT. Total cell proteins show a net increase in both
phospho-AKT and total AKT (Figure 3D). The decrease
of phospho-AKT in the membrane and cytoplasm and its
upregulation in the nucleus is associated with B7-H1 re-
distribution after doxorubicin treatment.
B7-H1 inhibition increases the apoptotic effect of 
doxorubicin in breast cancer cells
Recently, cell surface B7-H1 has been demonstrated to
play an anti-apoptotic role in a mouse cancer model [31].
Other studies showed that phospho-AKT, as an anti
apoptotic molecule, is upstream of B7-H1 [29,30]. There-
fore, we investigated whether the presence of B7-H1 plays
a role in apoptosis. In the present study, we investigated
its possible anti-apoptotic role in human breast cancer
cells. We inhibited B7-H1 using a specific siRNA before
treating MDA-MB-231 cells with doxorubicin. B7-H1-
siRNA treatment resulted in downregulation of B7-H1
Figure 3 The effect of doxorubicin on B7-H1 cellular distribution. A) Representative confocal immunofluorescence image of MDA-MB-231 cells 
monolayer after drug treatments. The overlay of B7-H1 (green) DAPI (nucleus blue) is shown as bluish white color. Numbers beside drugs indicates 
the concentration in μg/mL. B and D) Western blot showing B7-H1 and phospho-AKT expression respectively in different protein fractions of MDA-
MB-231 cells treated with doxorubicin for 72 hours. C) Western blot showing B7-H1 expression in different protein fractions of T47 D cells treated with 
doxorubicin for 72 hours. GAPDH was used as control as well as for quantification of the B7-H1 expression.
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cell surface expression from 91% to 49% (Figure 4A mid-
dle). Interestingly, there was an increase in apoptosis
from 50 ± 14% in control-siRNA treated to 75 ± 15% in
B7-H1-siRNA transfected cells after doxorubicin treat-
ment (P < 0.001). This translates into a 1.5-fold increase
in the specific doxorubicin induced apoptosis (SDA) in
the B7-H1 negative cells treated with B7-H1-siRNA
inhibitor (Figure 4A top) indicating an anti-apoptotic role
of B7-H1 in breast cancer cells (the columns are means
and error bars are SEMs). Similar results were obtained
using a different B7-H1-siRNA (CD274: siRNA ID =
s26548) inhibitor (Additional file 1) confirming the spe-
cific inhibition effect of B7-H1. Cell shrinkage, a typical
feature of apoptosis is shown at the bottom of Figure 4A.
The anti-apoptotic role of B7-H1 is PI3K/AKT pathway 
dependent
Because B7-H1 is a downstream target of AKT, we inves-
tigated whether the anti-apoptotic effect of B7-H1 is
associated with the AKT pathway. We tested the effect of
inhibiting AKT phosphorylation using PI3K/AKT inhibi-
tor (LY294002) on B7-H1 expression and function. Inter-
estingly, the inhibition of the AKT pathway resulted in a
two-fold increase in the specific doxorubicin induced
apoptosis (P = 0.016) (Figure 4B top). The columns are
means and error bars are SEMs. The effect of inhibiting
PI3K/AKT pathway on B7-H1 expression was also inves-
tigated. While AKT Inhibition partially decreased cell
surface B7-H1 expression, doxorubicin treatment of the
Figure 4 The effect of doxorubicin on B7-H1 and AKT expression and induction of apoptosis. A) Column chart of the FACS data showing the 
effect of siRNA-B7-H1 inhibition on the percentage of apoptosis induced after 48-hours treatment of MDA-MB-231 cells with doxorubicin (n = 6, **in-
dicated P < 0.001) (Top panel), representative FACS data of one of the experiments (middle panel) and image of the cells right before harvesting (bot-
tom panel). B) Column chart of the FACS data showing the effect of specific AKT-inhibitor (LY294002) on B7-H1 expression and induction of apoptosis 
in MDA-MB-231 cells after 48 hours doxorubicin treatment (n = 5, **indicates P = 0.016) (Top panel), representative FACS data of one of the experi-
ments (middle panel) Diamond, total percentage of apoptotic cells, Spade, numbers in brackets are specific doxorubicin induced apoptosis (SDA) cal-
culated by subtracting the percent of apoptotic cells in non-treated control. Image of the cells right before harvesting is indicated in the bottom panel. 
(The columns are means and error bars are SEMs in the top panel of A and B). C) Western blot for nuclear proteins from the same cells as in B stained 
with B7-H1 or GAPDH. D) Representative immunofluorescence images of the same cells as in B stained with a specific antibody for phospho-AKT 
(green). E) Cytoplasmic and nucleus AKT were quantified manually from the presented image shown in D. Nuclei were counterstained with DAPI (Red).
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inhibited cells synergistically decreased cell surface B7-
H1 expression (from 60 to 30%) (Figure 4B middle). Cell
shrinkage, a typical feature of apoptosis is shown at the
bottom of Figure 4B. As shown in Figure 3B there was an
upregulation of B7-H1 expression in the nucleus of doxo-
rubicin treated cells. However, doxorubicin treatment of
PI3K-inhibited cells had a significant low expression of
the nuclear B7-H1 (Figure 4C). The increase of the
nuclear B7-H1 in PI3K-inhibited cells, in the absence of
doxorubicin treatment, may be due to a reverse signal of
B7-H1 as it has been suggested recently [32]. Our data
suggest that doxorubicin-dependent upregulation of B7-
H1 in the nucleus is in part dependent on the AKT path-
way. To confirm our finding for the translocation of phos-
pho-AKT to the nucleus, we stained the cells with an
antibody-specific for phospho-AKT. Doxorubicin redis-
tributed phospho-AKT from the membrane and cyto-
plasm to the nucleus consistent with the B7-H1 nuclear
translocation (Figure 4D, E). Overall these results show
that doxorubicin upregulates B7-H1 in the nucleus via an
AKT-dependent mechanism to oppose the apoptosis of
the cells. On the other hand, doxorubicin downregulates
B7-H1 from the cell membranes through an unknown,
AKT-independent pathway.
Doxorubicin decrease cell surface expression of B7-H1 in 
vivo
To confirm our in vitro observation of doxorubicin down-
regulation of B7-H1 in an in vivo system, we used a
mouse model where we xenotransplanted MDA-MB-231
in nude mice in the mammary fat pad to closely mimic
human breast cancer. When tumors reached 7 mm some
of the mice were not treated (n = 2), while others (n = 2)
were treated with doxorubicin at 10 mg/Kg. Tumor tis-
sues from treated and untreated mice were surgically
removed. In addition, we removed the heart as heart cells
are known to constitutively express B7-H1 [15]. The
tumor tissues had lower expression of B7-H1 after doxo-
rubicin treatment as shown in Figure 6. Interestingly, the
nuclear expression of B7-H1 was clear after doxorubicin
treatment. Remarkably, there was a significant decrease
in B7-H1 expression in the heart tissues of the treated
mice where most heart myocytes were negative for B7-
H1 staining and very few nuclear B7-H1 expressions
could be seen (Figure 5). In conclusion, doxorubicin
downregulates surface expression of B7-H1 in tumor cells
as well as normal heart tissue in vivo, and triggers its re-
distribution into nuclei confirming the physiological rele-
vance of our in vitro findings.
Discussion
The unique ability of anthracyclines to induce immuno-
genic tumor cell death has triggered many studies in
order to understand the immunomodulatory effect of this
family of chemotherapeutic agents. However, to our
knowledge, the effect of anthracyclines on co-stimulation
has never been investigated, despite its central role in the
adaptive immune system. B7-H1 is a negative co-stimula-
tory molecule that is expressed in many cancers, where it
is believed to contribute to the escape of tumors from
immune recognition [33]. In this study, we demonstrated
doxorubicin-mediated downregulation of B7-H1 surface
expression and its localization to the nucleus.
We have previously reported the aberrant expression of
B7-H1 in breast cancer tissues from 69 patients, some of
which received chemotherapy while others did not
[20,25,27]. However, we were not able to draw a conclu-
sion on the effect of chemotherapy on the expression of
B7-H1 in the corresponding tissues due to several factors.
First, the tissue samples were taken after surgery, which is
typically scheduled weeks after chemotherapy treatment,
giving time for patient's blood counts to normalize. Addi-
tionally, the patients received a cocktail of chemothera-
peutic agents which could have different effects on B7-H1
expression. Therefore, in this current study we took an in
vitro approach to further test the specific effect of differ-
ent chemotherapeutic agents on B7-H1 expression. We
then confirmed our results in vivo mouse models where
samples can be taken as soon as three to five days after
treatment.
Doxorubicin, as one of the most effective anthracy-
clines drugs, specifically decreased B7-H1 expression in
two cell lines known to constitutively express B7-H1
(MDA-MB-231 and SKBr3), while the other chemothera-
peutic agents (cisplatin and docetaxel) did not have any
significant effect on B7-H1 expression. It is important to
note that the modulation of B7-H1 was observed at clini-
cally relevant concentrations [34]. Interestingly, the effect
of doxorubicin on B7-H1 expression was more prominent
than daunorubicin. This is consistent with previous
reports which indicate that doxorubicin has more immu-
nogenic effect on cancer cells than daunorubicin [35]. On
the other hand, mitoxantrone, which is remotely related
to other anthracyclines, had no significant effect on B7-
H1 cell surface expression. This may be due to the lack of
the daunosamine sugar moiety and a substituted agly-
conic anthraquinone [36]. Many investigators reported
an effect of chemotherapeutic agents on co-stimulatory
molecules such as B7.1. For example, Vereecque et al [37]
reported an increase in B7.1 expression in Da1-3b leuke-
mic cells following treatment with Ara-C and a slight
decrease in B7-H1 expression. Similarly, the Mokyr group
[38] reported upregulation of B7.1 and B7.2 molecules
after treatment with L-PAM in MOPC-315 tumor bear-
ing mice. However, Zhang et al [39] reported a negative
co-stimulatory effect of different groups of chemothera-
peutic agents, namely paclitaxel and etoposide, in breast
cancer cells due to the upregulation of B7-H1. This sug-Ghebeh et al. Breast Cancer Research 2010, 12:R48
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gests that different chemotherapeutic agents may have
different effects on co-stimulatory molecules. In this
regard, it is also important to note that none of the previ-
ous reports studied anthracyclines' effects on co-stimula-
tion. Anthracyclines are unique among many
chemotherapeutic agents in their ability to induce immu-
nogenic apoptotic death in cancer cells. This has clearly
been established by others who demonstrated that among
various chemotherapeutic agents tested, anthracyclines
were the only effective agents that provided mice with
enhanced immunity when further challenged with tumor
cells [10,40]. The effect of doxorubicin on B7-H1
reported in this study might, at least partially, explain
doxorubicin's ability to make tumor cells immunogenic
beside the other above discussed mechanisms.
Many chemotherapeutic agents, including doxorubicin
and docetaxel, kill cancer cells through apoptosis, a pro-
cess of cell death that is accompanied by cell membrane
flip-flop leading to phosphatidylserine exposure, cell
shrinkage and bleb formation; yet the cell membrane
remains intact. The decrease of B7-H1 expression
observed in the present study was not due to apoptotic
membrane flipping. Moreover, docetaxel, which induced
apoptosis in large numbers of cells, had no significant
effect on B7-H1 expression demonstrating the specific
effect of doxorubicin on B7-H1 surface downregulation.
In a mouse model, it has been shown that B7-H1 cell
surface expression has an anti-apoptotic effect, where it is
described as a molecular shield to protect cells from
apoptosis [31]. Using specific B7-H1-siRNA, we have
knocked down B7-H1 and have shown that doxorubicin
induced more significant apoptosis, indicating a possible
anti-apoptotic role for B7-H1 in breast cancer cells. How-
ever, the precise mechanism by which B7-H1 protects
cells from apoptosis is unknown.
This is the first report to demonstrate the presence of
nuclear expression of B7-H1 in breast cancer cells and its
upregulation after drug treatment. The nuclear localiza-
tion of B7-H1 suggests a function that extends beyond its
role in inhibiting T lymphocytes. Our observation, that
doxorubicin upregulates B7-H1 specifically in the nucleus
and the significantly enhanced apoptosis after following a
combination of B7-H1 knockdown and doxorubicin
treatment, led us to speculate that the anti-apoptotic
function of B7-H1 is due to its nuclear localization. The
nuclear translocation of B7-H1 might allow its interac-
tion with the apoptotic machinery of cells to regulate
apoptosis. It has been reported that the nucleolus con-
tains many anti-apoptotic molecules that promote cell
survival after exposure to stress (Reviewed in [41]). At the
clinical level, these findings might encourage targeting
Figure 5 Effect of doxorubicin on the in vivo expression of B7-H1. Representative Immunohistochemical images (× 540) for B7-H1 (brown) ex-
pression in doxorubicin-treated and untreated mice. Shown are sections for tumors formed from xenotransplanted MDA-MB-231 cells in nude mice 
as well as heart tissues of the nude mice. Nuclei are counterstained with a light hematoxylin to show the nuclear B7-H1 expression. Arrows indicates 
the nuclear staining of B7-H1.
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B7-H1 expression in conjunction with doxorubicin treat-
ment.
The upregulation of phospho-AKT in the nucleus fol-
lowing doxorubicin treatment has been reported previ-
ously [42,43]. A subsequent study revealed an
enhancement of apoptosis after PI3K/AKT pathway inhi-
bition [44]. Using Western blot and immunofluorescence
assays, we showed concurrent B7-H1 and phospho-AKT
translocation to the nucleus. Furthermore, we demon-
strated a similar effect of AKT and B7-H1 as anti-apop-
totic molecules. Most importantly, B7-H1 up-regulation
was inhibited using the PI3K/AKT inhibitor LY294002.
This suggests that B7-H1 is upregulated in the nucleus via
an AKT-dependent pathway. This is supported by previ-
ous studies demonstrating that B7-H1 is downstream of
the PI3K/AKT pathway in breast cancer cells. However,
these studies investigated B7-H1 levels in total cellular
proteins and not the nuclear fraction [29,30]. It is impor-
tant to mention that LY294002 can also inhibit several
PI3K-like kinases including mTOR, PDK2 and CK2
[45,46]. Therefore, it is possible that LY294002 is also
inducing apoptosis through other pathways than PI3K/
AKT and this requires further investigation.
The results of the current study demonstrate that the
translocation of B7-H1 from the membrane to the
nucleus could not be inhibited after PI3K/Akt pathway
inhibition; rather there was a synergistic decrease in the
cell surface of B7-H1 following PI3/Akt pathway inhibi-
tion and doxorubicin treatment. This suggests that the
PI3K/Akt pathway is not involved in the doxorubicin-
dependent downregulation of cell surface B7-H1. In con-
clusion, our results suggest that B7-H1 re-distribution by
doxorubicin is controlled by two pathways; an AKT-
dependent pathway that is dominant in the nucleus and
an unknown AKT-independent pathway that is dominant
in the cell surface.
The in vivo effect of doxorubicin on B7-H1 expression
is important as cells in culture do not necessarily recapit-
ulate the behavior of cells in vitro. More importantly, dox-
orubicin's effect on B7-H1 expression was not limited to
xenotransplanted cancer cells, as similar results were
observed clearly in murine cardiac tissues. These novel
findings of B7-H1 downregulation in heart tissue follow-
ing doxorubicin treatment may explain the cardiomyo-
toxicity that is reported in patients receiving this
chemotherapy, beside other previously reported mecha-
nisms [47]. Downregulation of B7-H1 in heart tissues fol-
lowing doxorubicin treatment may render cardiac cells a
potential target for autoimmunity, which is an area for
further investigation.
Conclusions
Our findings demonstrate the presence of nuclear expres-
sion of B7-H1 in breast cancer cells and its upregulation
after drug treatment and explain the previously reported
immunomodulatory effect of anthracyclines on cancer
cells providing a possible link between immunoresistance
and chemoresistance. Finally our results suggest the use
of dual combinatorial agents to inhibit B7-H1 beside che-
motherapy in breast cancer patients.
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